[Question] is 97.6% actually fine or am I being sold a rounding error
Result first, context after: is 97.6% actually fine or am I being sold a rounding error. Everything below is how it was ordered, stored and sent.
Since the title puts numbers in the shop window: 97.6%.
Sent a vial to Medutest because there was almost nothing on file for this compound. 98.3% against a claimed 97.5%, and I posted it because the log needs entries.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Please do not ask me what dose you should be on. I genuinely do not know and neither does anyone else here.
best — the order this archive was captured in
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
Independent result added to the log. Thank you for paying for it — there are very few on this compound.
Monotherapy arm or combination arm?
That is preclinical work and the thread is treating it as a human finding.
Careful — that is a dosing intuition carried over from another board and there is no basis for it here.
read the combination arms separately from the monotherapy arms
do not assume the dosing intuitions from the GLP-1 boards transfer
phase 3 data will change most of what gets said here
Why this compound is not simply another agonist, which is how it gets described everywhere else.
Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a different axis from the incretin system, not a parallel version of it. That is why the combination story is interesting: two mechanisms that address appetite differently, rather than more agonism at one receptor.
It is also why the dosing intuitions people bring from the semaglutide and tirzepatide boards do not transfer. Different receptors, different exposure-response, and no published schedule anybody here can reason from.
Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.
That result is preclinical. Worth flagging, since the thread has been reading it as human data.
Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.
Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.
Is there any independent purity data on this compound that you have seen?
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.
long-acting amylin is the whole point of the molecule
Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.
- 1That is preclinical work and the thread is treating it as a human finding.6 comments in this branch · started by u/hana_pereira